Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement 

Rhea-AI Summary

Plus Therapeutics (Nasdaq: PSTV) announced it has regained compliance with Nasdaq's minimum bid price rule. Nasdaq confirmed the company's closing bid price was at or above $1.00 per share for 10 consecutive business days from April 6, 2026 to April 17, 2026.

Nasdaq advised the matter is closed, restoring full compliance with Listing Rule 5550(a)(2).

Positive

• Nasdaq compliance restored after 10 consecutive business days
• Closing bid met $1.00 threshold from Apr 6–Apr 17, 2026
• Listing matter officially closed by Nasdaq

Negative

• Previous deficiency indicated prior period of sub-$1.00 trading

News Market Reaction – PSTV

-2.19%

9 alerts

-2.19% News Effect

+4.6% Peak Tracked

-8.9% Trough Tracked

-$1M Valuation Impact

$54.90M Market Cap

0.3x Rel. Volume

On the day this news was published, PSTV declined 2.19%, reflecting a moderate negative market reaction. Argus tracked a peak move of +4.6% during that session. Argus tracked a trough of -8.9% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $54.90M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement confirms that Plus Therapeutics regained compliance with Nasdaq’s $1.00 minimum bi...

Analysis

This announcement confirms that Plus Therapeutics regained compliance with Nasdaq’s $1.00 minimum bid rule after maintaining the threshold for 10 consecutive business days. It follows an active stretch of FDA designations, coverage expansions, and senior hires aimed at advancing REYOBIQ and CNSide. Investors may monitor future regulatory milestones, commercial adoption metrics, and additional listing-related communications as key indicators of how the company consolidates this improved status.

Key Figures

Nasdaq minimum bid price: $1.00 per share Compliance measurement window: 10 consecutive business days Start of compliance period: April 6, 2026 +1 more

4 metrics

Nasdaq minimum bid price $1.00 per share Nasdaq Listing Rule 5550(a)(2) compliance threshold

Compliance measurement window 10 consecutive business days Closing bid at or above $1.00 from Apr 6–17, 2026

Start of compliance period April 6, 2026 First day with closing bid at or above $1.00

End of compliance period April 17, 2026 Tenth consecutive day meeting $1.00 bid price

Historical Context

5 past events · Latest: Apr 15 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 15	Executive appointment	Positive	+4.0%	New VP for value strategy and HEOR to support CNSide and REYOBIQ.
Apr 09	Executive appointment	Positive	+23.7%	New Chief Development Officer to advance CNS radiopharmaceutical pipeline.
Apr 08	Orphan designation	Positive	+8.6%	FDA Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas.
Apr 07	Reimbursement code	Positive	-12.3%	AMA PLA CPT code for CNSide CSF Tumor Cell Enumeration test.
Apr 02	Coverage expansion	Positive	-8.6%	Highmark coverage expanding CNSide assay access to ~75 million lives.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news usually draws positive reactions, but reimbursement-related diagnostics updates have twice coincided with negative moves.

Recent Company History

Over the past month, Plus Therapeutics reported multiple strategic and regulatory milestones. Governance and management evolved with a new director on Mar 26 and senior hires on Apr 9 and Apr 15, each tied to advancing CNS-focused programs and commercialization. The company expanded CNSide reimbursement coverage on Apr 2 and secured an AMA PLA code on Apr 7, though both saw negative price reactions. By contrast, the Apr 8 FDA Orphan Drug Designation for REYOBIQ and subsequent leadership appointments aligned with notable positive price moves, framing today’s compliance update within an active, execution-heavy period.

Key Terms

minimum bid price requirement, closing bid price

2 terms

minimum bid price requirement regulatory

"regained compliance with the minimum bid price requirement set forth in Nasdaq..."

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

closing bid price financial

"the closing bid price of the Company’s common stock was at or above $1.00..."

The closing bid price is the last price that a buyer was willing to pay for a security at the end of the trading day. It reflects the final visible demand for the stock — like the last offer someone makes for a used car before a yard closes — and helps investors gauge market interest, set valuations, and mark portfolios to market for that day.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced that it has received notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

Nasdaq determined that, for the 10 consecutive business days from April 6, 2026 to April 17, 2026, the closing bid price of the Company’s common stock was at or above $1.00 per share. Accordingly, Nasdaq has advised that the matter is now closed.

About Plus Therapeutics 

Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing and future potential commercialization of its products.

Investor Contact
CORE IR
investor@plustherapeutics.com

FAQ

What did Plus Therapeutics (PSTV) announce about Nasdaq compliance on April 21, 2026?

They announced Nasdaq confirmed the company regained compliance with the minimum bid price requirement. According to the company, the closing bid price was at or above $1.00 for 10 consecutive business days from April 6 to April 17, 2026, and Nasdaq closed the matter.

How long did PSTV need to maintain a $1.00 closing bid to regain Nasdaq compliance?

PSTV needed 10 consecutive business days with a closing bid at or above $1.00. According to the company, that period ran from April 6, 2026 to April 17, 2026, meeting Nasdaq Listing Rule 5550(a)(2) requirements.

Does Nasdaq closing the matter mean PSTV faces no further listing risk now?

Nasdaq's closure confirms compliance for the specified period but does not guarantee future status. According to the company, the stock met the rule for the 10-business-day window, but future price declines could reopen deficiency procedures.

What immediate effect does regaining Nasdaq compliance have for PSTV shareholders?

Regaining compliance preserves the company's Nasdaq listing and reduces near-term delisting risk. According to the company, Nasdaq confirmed the $1.00 closing bid requirement was satisfied, which helps maintain market access and investor confidence.

Which Nasdaq rule did PSTV satisfy to regain compliance and why does it matter?

PSTV satisfied Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement. According to the company, meeting the $1.00 closing bid threshold for 10 consecutive business days prevented delisting procedures tied to sustained low share price.